A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05353257 |
|
Recruitment Status :
Recruiting
First Posted : April 29, 2022
Last Update Posted : March 4, 2024
|
Sponsor:
Shanghai Henlius Biotech
Information provided by (Responsible Party):
Shanghai Henlius Biotech
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | December 30, 2024 |
| Estimated Study Completion Date : | June 30, 2026 |